SCHEMBL20091035

SCHEMBL20091035

CCCC(C)/C=C/c1c(F)cccc1Cl

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 4/20 0.44
MAT2A P31153 1/20 0.44
TDP1 Q9NUW8 2/20 0.42
SMN1; SMN2 Q16637 6/20 0.40
HPGD P15428 6/20 0.40
LMNA P02545 2/20 0.40
ALOX12 P18054 1/20 0.40
ATM Q13315 1/20 0.40
RAB9A P51151 8/20 0.40
MAPT P10636 3/20 0.40
KMT2A Q03164 3/20 0.40
MDM4 O15151 1/20 0.40
MDM2 Q00987 1/20 0.40
NPC1 O15118 4/20 0.39
KDM4E B2RXH2 3/20 0.39
ALDH1A1 P00352 2/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
HTT P42858 2/20 0.38
POLB P06746 1/20 0.36
HCRTR1 O43613 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19053751 0.88 KCNH2 (0.47) KCNH2MAT2ATDP1SMN1; SMN2HPGD
SCHEMBL19099251 0.83 KCNH2 (0.46) KCNH2MAT2ATDP1SMN1; SMN2HPGD
SCHEMBL20090999 0.81 P2RX7 (0.37)
SCHEMBL9967742 0.80 KCNH2 (0.51) KCNH2MAT2ATDP1SMN1; SMN2HPGD
SCHEMBL19879653 0.78 KCNH2 (0.49) KCNH2MAT2ATDP1SMN1; SMN2HPGD
SCHEMBL20090979 0.74 NFE2L2 (0.44)
SCHEMBL257070 0.74 KCNH2 (0.51) KCNH2MAT2ATDP1SMN1; SMN2HPGD
SCHEMBL14416464 0.74 KCNH2 (0.51) KCNH2MAT2ATDP1SMN1; SMN2HPGD
SCHEMBL20091000 0.74 LMNA (0.41) KCNH2MAT2ATDP1SMN1; SMN2HPGD
SCHEMBL16067619 0.71 KCNH2 (0.56) KCNH2MAT2ATDP1SMN1; SMN2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10442798-B2 Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease LYCERA CORPORATION (US) 2019-10-15 US disclosed
US-10421751-B2 Dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease LYCERA CORPORATION (US) 2019-09-24 US disclosed
US-20180111922-A1 DIHYDRO-2H-BENZO[b][1,4]OXAZINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATEMENT OF DISEASE LYCERA CORPORATION 2018-04-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180111922-A1 DIHYDRO-2H-BENZO[b][1,4]OXAZINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATEMENT OF DISEASE RORB, RORA, RORC KCNH2 3770/4885MAT2A 2617/4885TDP1 4647/4885
US-10442798-B2 Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease RORA, RORC, RORB KCNH2 3127/4885MAT2A 2769/4885TDP1 4421/4885
US-10421751-B2 Dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease RORB, RORA, RORC KCNH2 3274/4885MAT2A 3130/4885TDP1 4563/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.